CoImmune, Inc. Announces Appointment of Ed Baracchini to Board of Directors
DURHAM, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, today announced the appointment of Dr. Edgardo Baracchini, to the Company’s board of directors.
Dr. Baracchini brings a wealth of biotechnology industry and financial expertise, as well as significant prior board level experience, to the CoImmune board of directors. Dr. Baracchini has over 25 years of experience in structuring and negotiating research and development partnerships, mergers and acquisitions, and licensing agreements as a biotech industry executive. He has personally negotiated more than 80 business transactions with multinational pharmaceutical firms, biotechnology companies, and prominent universities. He has significant experience in alliance management, strategic planning, and IR/PR. Additionally, Dr. Baracchini has been a key member of executive teams that have successfully completed two IPOs and has previously worked in biotech companies such as Imago Biosciences, Xencor, Inc., Metabasis Therapeutics, Elitra Pharmaceuticals, Warner Lambert, Agouron Pharmaceuticals, and Ionis Pharmaceuticals.
"We are excited to welcome Dr. Baracchini to the CoImmune board," stated Dr. Charles Nicolette, chief executive officer and member of the board of directors. "Ed has considerable biotechnology industry and financial expertise that will benefit CoImmune as we seek to advance our novel pipeline of cell-based immunotherapies directed at important diseases, including advanced renal cell carcinoma and acute lymphoblastic leukemia. In particular, Ed’s financial and strategic expertise will complement the expertise of the current board members as well as add a valuable new perspective."
Dr. Baracchini has served on a number of boards of directors of companies in the biotechnology industry and is currently serving on the board of directors at INmune Bio, Inc., La Jolla, California, and 4D Pharma, plc., United Kingdom.
Dr. Baracchini obtained his B.S. in Microbiology at the University of Notre Dame, a Ph.D. in Molecular and Cell Biology at University of Texas at Dallas, and an MBA at University of California, Irvine.
About CoImmune, Inc.
CoImmune is a privately held clinical stage biotechnology company specializing in the development of immuno-oncology therapies based on its two proprietary platform technologies. The first platform is an autologous RNA-loaded dendritic cell technology for solid tumors that specifically targets each patient’s unique tumor antigens. The second platform is an allogeneic CAR-CIK technology that is a variation on CAR-T therapy with greatly reduced toxicity while retaining strong efficacy.
For more information, visit www.coimmune.com.
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
TigerGraph, Inc.8.4.2021 15:01:29 CEST | Press release
TigerGraph’s Graph + AI Summit 2021 to Feature 40+ Sessions, Live Workshops and Speakers from JPMorgan Chase, NewDay, Pinterest, Jaguar Land Rover and More
Agillic A/S7.4.2021 09:01:28 CEST | Press release
Agillic launches a new fast and advanced SMS editor to help clients deliver personalised SMS experiences
TigerGraph, Inc.30.3.2021 15:29:56 CEST | Press release
Technical University of Denmark uses TigerGraph to help find more effective treatments for acute lymphoblastic leukemia
Møns Bank A/S26.3.2021 07:03:33 CET | Pressemeddelelse
Indkaldelse til ekstraordinær generalforsamling 19. april 2021
Sika AG26.3.2021 07:02:09 CET | Press release
SIKA ACQUIRES FLOORING ADHESIVES BUSINESS IN THE USA
Arcadis N.V.26.3.2021 07:01:59 CET | Press release
Arcadis reports transactions under its current share buyback program
Terranet26.3.2021 07:01:48 CET | Press release
Warrants of series (2020:2) TO2 B we subscribed to approximately 94.9 percent and TerraNet Holding AB receives approximately SEK 38.3 million
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom